Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07856017
Recruiting Observational

Development of an Intraoperative Adaptive Biopsy System for Prostate Cancer: Integrating Imaging Navigation With Metabolic Feedback for Dynamic Decision-Making

NCT07856017 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Zhongshan Hospital
Phase
Observational
Started
2026-07-21
Last updated
2026-10-02

Condition(s) studied

Prostate Cancer (Adenocarcinoma)Prostate Cancer (Diagnosis)

Study summary

Development of an Intelligent System Integrating Preoperative Imaging and Real-Time Intraoperative Metabolic Feedback to Dynamically Optimize Biopsy core Placement for Individualized Precision Sampling.

Eligibility

Sex
MALE
Min age
55 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥55 years; 2. Indication for prostate biopsy; 3. Availability of total prostate-specific antigen (tPSA), free PSA (fPSA) levels, and multiparametric MRI (mpMRI) results within 1 month prior to biopsy. Exclusion Criteria: 1. Pathological diagnosis of malignancies other than prostatic acinar adenocarcinoma; 2. Concomitant malignant tumors potentially affecting imaging findings (e.g., rectal, bladder, or testicular cancer); 3. Cachexia or organ function decompensation.

Primary outcome measure(s)

  • Mean number of biopsy cores required to achieve a definitive diagnosis in the adaptive biopsy group — After 8 weeks of the enrollment process was completed

Trial sites (4)

FacilityCityRegionStatus
Minhang Hospital, Fudan University Shanghai China Recruiting
Shanghai Geriatric Medical Center Shanghai China Recruiting
Xuhui Hospital, Fudan University Shanghai China Recruiting
Zhongshan Hospital, Fudan University Shanghai China Recruiting

More Shanghai Zhongshan Hospital trials in China

A Prospective Multicenter Clinical Study： IntracOronary neaR-Infrared Spectroscopy and OptIcal Coherence Tomography for Evaluating Coronary vulNerable Plaque in Patients With diabeTes Recruiting
Trends and Risk Factors of Adverse Cardiovascular and Cerebrovascular Events After Primary PCI Recruiting
Improve the Strategies of Endoscopic and Interventional Treatment of Gastroesophageal Hemorrhage in Portal Hypertension Recruiting
In Vivo CAR-T for Refractory Graves' Disease Recruiting
The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial Recruiting

Other trials for the same condition

Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer Starting soon
Plasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis Recruiting
The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer Recruiting
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) Recruiting
Theranostic Applications of Radionuclides in Prostate Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07856017 on ClinicalTrials.gov ↗ ← All trials in China